# The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

> **NCT05786066** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 30 (estimated)

## Conditions studied

- Depressive Disorder
- Major Depressive Disorder
- Bipolar Disorder
- Post Traumatic Stress Disorder
- Suicidal Ideation

## Interventions

- **DRUG:** Perampanel 6 MG
- **DRUG:** Ketamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05786066
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2033-03
- **Final completion:** 2033-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786066, "The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05786066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*